InMed Pharmaceuticals (NASDAQ:INM) Issues Quarterly Earnings Results

InMed Pharmaceuticals (NASDAQ:INM) released its quarterly earnings results on Wednesday. The company reported ($3.64) EPS for the quarter, Zacks reports. InMed Pharmaceuticals had a negative net margin of 137.41% and a negative return on equity of 65.74%.

InMed Pharmaceuticals Stock Performance

InMed Pharmaceuticals stock traded up $0.12 on Wednesday, reaching $3.20. 160,065 shares of the stock were exchanged, compared to its average volume of 1,024,570. The stock has a market cap of $2.30 million, a PE ratio of -0.23 and a beta of 0.19. The company has a current ratio of 5.07, a quick ratio of 4.22 and a debt-to-equity ratio of 0.08. InMed Pharmaceuticals has a twelve month low of $2.41 and a twelve month high of $15.70. The firm has a fifty day moving average price of $4.37 and a two-hundred day moving average price of $4.74.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.